Kailera Therapeutics R&D increased by 599.6% to $70.87M in Q1 2026 compared to the prior quarter.
Analysis
StatementIncome Statement
SectionOperating Expenses
CategoryGrowth
SignalContext dependent
VolatilityModerate
First reportedQ1 2025
Last reportedQ1 2026May 26, 2026
How to read this metric
Higher spending signals a commitment to innovation and future product launches, whereas significant cuts may indicate a shift toward short-term profitability.
Detailed definition
Research and development expenses represent the costs incurred to discover new products, improve existing technologies,...
Peer comparison
Highly comparable across pharmaceutical and medical device peers, where R&D intensity is a key metric for long-term valuation.
Metric ID:
research_and_developmentHistorical Data
2 periods
| Q1 '25 | Q1 '26 | |
|---|---|---|
| Value | $10.13M | $70.87M |
| QoQ Change | — | +599.6% |
| YoY Change | — | +599.6% |
Range$10.13M – $70.87M
Avg YoY Growth+599.6%
Median YoY Growth+599.6%
R&D at Other Companies
Frequently Asked Questions
- What is Kailera Therapeutics 's r&d?
- Kailera Therapeutics (KLRA) reported r&d of $70.87M in Q1 2026.
- What does r&d mean?
- The money spent on creating new products or improving existing ones to drive future growth.